← OPKO HEALTH, INC. (OPK) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
OPKO HEALTH, INC. (OPK)
Pharmaceutical Preparations · market cap $1.3B · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
18
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
OPKO Health (OPK) is a diversified diagnostics and pharmaceutical company with a market cap of ~$899M, trading at ~$1.19 per share. The company operates across multiple therapeutic areas including growth hormone deficiency, chronic kidney disease, and type 2 diabetes, with a sprawling pipeline spanning Phase 2 and Phase 3 assets. Revenue has declined sharply from $1.775B in 2021 to $607M in 2025, while net losses have been erratic and persistent.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| LY2944876 | Phase 2 | Diabetes Mellitus, Type 2 |
| TT223 with Metformin and/or TZD | Phase 2 | Diabetes Mellitus, Type 2 |
| Genotropin | Phase 3 | Growth Hormone Deficiency |
| OPK-88003 | Phase 2 | Type 2 Diabetes Mellitus |
| ELND005 (scyllo-inositol) | Phase 2 | Alzheimer's Disease |
| ELND005 | Phase 2 | Alzheimer's Disease |
| bevasiranib | Phase 2 | Diabetic Macular Edema |
| CTAP101 Capsules | Phase 3 | Chronic Kidney Disease |
| MOD-4023 | Phase 3 | Pediatric Growth Hormone Deficiency |
| CTA018 cream | Phase 2 | Psoriasis |
| Rayaldee | Phase 2 | COVID-19 |
| Cohort 1 CTAP101 Capsules- 60µg | Phase 3 | Chronic Kidney Disease |
| Somatropin | Phase 3 | Pediatric Growth Hormone Deficiency |
| MDX2003 | Phase 2 | Lymphoma |
| CTAP101 30 μg capsules | Phase 3 | Chronic Kidney Disease |
| MDX2004 | Phase 2 | Advanced Tumors |
| MDX2001 | Phase 2 | Biliary Tract Cancer |
| CTA018 Injection | Phase 2 | Chronic Kidney Disease |
Price & technical context
3-month
+3.3%
6-month
+38.9%
12-month
+1.3%
52-wk range
$1.10–$1.73
vs 50-day MA
+5.4%
vs 200-day MA
+18.9%
Realized vol
51.4%
Max drawdown
-43.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OPK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.